Thelansis

Osteogenesis Imperfecta (OI) Market Outlook Thelansis’s “Osteogenesis Imperfecta (OI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Osteogenesis Imperfecta (OI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the ...

  Osteogenesis Imperfecta (OI) Market Outlook Thelansis’s “Osteogenesis Imperfecta (OI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Osteogenesis Imperfecta (OI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Osteogenesis Imperfecta (OI) Overview Osteogenesis imperfecta (OI), or brittle bone disease, is a genetic disorder affecting connective tissues due to abnormalities in the synthesis or processing of type I collagen. This condition increases susceptibility to bone fractures and reduces bone density. Other symptoms include blue sclerae, dentinogenesis imperfecta, short stature, and adult-onset deafness. Reports also indi...

  Osteogenesis Imperfecta (OI), or brittle bone disease, is a genetic disorder affecting connective tissues due to abnormalities in the synthesis or processing of type I collagen. This condition leads to increased susceptibility to bone fractures and reduced bone density. Other symptoms include blue sclerae, dentinogenesis imperfecta, short stature, and adult-onset deafness. Reports also indicate valvular insufficiencies and aortic root dilation. Milder symptoms include generalized laxity, easy bruising, hernias, and excessive sweating. Clinical manifestations range from nearly asymptomatic forms to severe cases (such as infants with crumpled ribs, fragile cranium, and long bone fractures incompatible with life) that increase perinatal mortality. OI is a rare genetic disease, often stemming from mutations in the COL1A1 and COL1A2 genes. The International Society of Skeletal Dysplasias classifies OI based on the mode of inheritance and genes involved: Osteogenesis Im...